U.S. markets closed
  • S&P 500

    4,070.56
    +10.13 (+0.25%)
     
  • Dow 30

    33,978.08
    +28.67 (+0.08%)
     
  • Nasdaq

    11,621.71
    +109.30 (+0.95%)
     
  • Russell 2000

    1,911.46
    +8.39 (+0.44%)
     
  • Crude Oil

    79.38
    -1.63 (-2.01%)
     
  • Gold

    1,927.60
    -2.40 (-0.12%)
     
  • Silver

    23.73
    -0.30 (-1.23%)
     
  • EUR/USD

    1.0874
    -0.0018 (-0.16%)
     
  • 10-Yr Bond

    3.5180
    +0.0250 (+0.72%)
     
  • GBP/USD

    1.2395
    -0.0012 (-0.10%)
     
  • USD/JPY

    129.8000
    -0.3530 (-0.27%)
     
  • BTC-USD

    23,407.79
    +410.90 (+1.79%)
     
  • CMC Crypto 200

    526.66
    +9.65 (+1.87%)
     
  • FTSE 100

    7,765.15
    +4.04 (+0.05%)
     
  • Nikkei 225

    27,382.56
    +19.81 (+0.07%)
     

Do You Think Merck & Co. (MRK) is an Attractive Investment?

Smead Capital Management, an investment management company, released its "Smead Value Fund" fourth quarter 2022 investor letter. A copy of the same can be downloaded here. In the fourth quarter, the fund delivered 13.72% compared to a 7.56% gain for the S&P 500 Index and a 12.42% rise for the Russell 1000 Value Index. However, in 2022, the fund lost 2.78% compared to an 18.11% decline in the S&P 500 and a 7.54% loss in the Russell 1000 Value Index. In addition, you can check the top 5 holdings of the fund to know its best picks in 2022.

Smead Capital Management highlighted stocks like Merck & Co., Inc. (NYSE:MRK) in the Q4 2022 investor letter. Headquartered in Kenilworth, New Jersey, Merck & Co., Inc. (NYSE:MRK) is a healthcare company. On January 23, 2023, Merck & Co., Inc. (NYSE:MRK) stock closed at $109.88 per share. One-month return of Merck & Co., Inc. (NYSE:MRK) was -2.00%, and its shares gained 38.28% of their value over the last 52 weeks. Merck & Co., Inc. (NYSE:MRK) has a market capitalization of $278.59 billion.

Smead Capital Management made the following comment about Merck & Co., Inc. (NYSE:MRK) in its Q4 2022 investor letter:

"Our favorable quarter was led by Merck & Co., Inc. (NYSE:MRK), Macerich (MAC) and Simon Property (SPG). Merck was a tower of power all year as investors decided that curing cancer was a worthy endeavor and there are many cancers left to turn immuno-oncology loose on."

Source: Unsplash

Merck & Co., Inc. (NYSE:MRK) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 82 hedge fund portfolios held Merck & Co., Inc. (NYSE:MRK) at the end of the third quarter which was 79 in the previous quarter.

We discussed Merck & Co., Inc. (NYSE:MRK) in another article and shared Mormon Church’s 15 biggest stock positions. In addition, please check out our hedge fund investor letters Q4 2022 page for more investor letters from hedge funds and other leading investors.

 

Suggested Articles:

Disclosure: None. This article is originally published at Insider Monkey.